A Comparison Study of Algorithms to Detect Drug–Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches

Minh Pham, Feng Cheng () and Kandethody Ramachandran ()
Additional contact information
Minh Pham: University of South Florida
Feng Cheng: University of South Florida
Kandethody Ramachandran: University of South Florida

Drug Safety, 2019, vol. 42, issue 6, No 6, 743-750

Abstract: Abstract Introduction It is important to monitor the safety profile of drugs, and mining for strong associations between drugs and adverse events is an effective and inexpensive method of post-marketing safety surveillance. Objective The objective of our work was to compare the accuracy of both common and innovative methods of data mining for pharmacovigilance purposes. Methods We used the reference standard provided by the Observational Medical Outcomes Partnership, which contains 398 drug–adverse event pairs (165 positive controls, 233 negative controls). Ten methods and algorithms were applied to the US FDA Adverse Event Reporting System data to investigate the 398 pairs. The ten methods include popular methods in the pharmacovigilance literature, newly developed pharmacovigilance methods as at 2018, and popular methods in the genome-wide association study literature. We compared their performance using the receiver operating characteristic (ROC) plot, area under the curve (AUC), and Youden’s index. Results The Bayesian confidence propagation neural network had the highest AUC overall. Monte Carlo expectation maximization, a method developed in 2018, had the second highest AUC and the highest Youden’s index, and performed very well in terms of high specificity. The regression-adjusted gamma Poisson shrinkage model performed best under high-sensitivity requirements. Conclusion Our results will be useful to help choose a method for a given desired level of specificity. Methods popular in the genome-wide association study literature did not perform well because of the sparsity of data and will need modification before their properties can be used in the drug–adverse event association problem.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-00792-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:6:d:10.1007_s40264-018-00792-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-00792-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().